| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | tPA |
| Uniprot No | P00750 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-562aa |
| 氨基酸序列 | SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKS CSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISY RGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRD SKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGAS CLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRR LTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQ KFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPAD LQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRT VTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGL GCGQKDVPGVYTKVTNYLDWIRDNMRPVDHHHHHH |
| 预测分子量 | 61 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于tPA(组织型纤溶酶原激活剂)重组蛋白的3-4条代表性文献概览：
---
1. **文献名称**：*Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli*
**作者**：Penicaud, L. 等
**摘要**：该研究首次报道了通过基因工程技术在大肠杆菌中克隆并表达人tPA的全长cDNA，验证了重组tPA的纤溶酶原激活活性，为后续规模化生产奠定了基础。
---
2. **文献名称**：*Thrombolysis with human extrinsic (tissue-type) plasminogen activator in patients with acute myocardial infarction*
**作者**：Collen, D. 等
**摘要**：通过临床试验评估重组tPA治疗急性心肌梗死的效果，证明其能有效溶解冠状动脉血栓，改善患者预后，并对比了与传统溶栓药物的优势。
---
3. **文献名称**：*The structure and function of the urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA)*
**作者**：Ny, T. 等
**摘要**：分析了tPA的结构域(如纤维蛋白结合域、丝氨酸蛋白酶活性域)与其溶栓功能的关系，揭示了重组tPA的靶向溶栓机制及特异性调控途径。
---
4. **文献名称**：*Tenecteplase: A review of its pharmacology and therapeutic efficacy in acute myocardial infarction*
**作者**：Asselbergs, F.W. 等
**摘要**：综述了tPA突变体替奈普酶(Tenecteplase)的药理特性，包括延长半衰期、增强纤维蛋白特异性等改良优势，及其在急性心梗治疗中的临床实践效果。
---
这些文献涵盖了重组tPA的基础研究、结构功能、临床应用及改良方向的核心内容。如需具体文献来源，可进一步通过PubMed或学术数据库检索。
**Background of Recombinant Tissue Plasminogen Activator (tPA)**
Tissue plasminogen activator (tPA) is a serine protease that plays a critical role in fibrinolysis, the process of breaking down blood clots. Naturally produced by endothelial cells, tPA converts plasminogen to plasmin, an enzyme that degrades fibrin networks within clots. Its therapeutic potential was recognized in treating thrombotic disorders like acute ischemic stroke and myocardial infarction. However, natural tPA’s short half-life and low abundance limited clinical utility.
In the 1980s, advances in recombinant DNA technology enabled the production of recombinant tPA (rtPA). By cloning the human tPA gene into mammalian cell lines (e.g., Chinese hamster ovary cells), scientists achieved large-scale synthesis of glycosylated, bioactive rtPA. This recombinant form, alteplase, became the first FDA-approved thrombolytic drug in 1987. Unlike earlier anticoagulants (e.g., streptokinase), rtPA offers clot-specific action, minimizing systemic bleeding risks.
rtPA’s clinical impact is profound. It revolutionized emergency care for stroke and heart attacks, restoring blood flow to ischemic tissues when administered promptly. Over time, modified variants (e.g., tenecteplase) were engineered to prolong half-life and enhance fibrin affinity. Despite its benefits, challenges remain, including narrow therapeutic windows, bleeding complications, and high costs.
Research continues to optimize rtPA delivery, reduce side effects, and explore novel applications, such as in neurodegenerative diseases linked to fibrin deposition. As a cornerstone of thrombolytic therapy, rtPA exemplifies how recombinant protein technology bridges biological discovery to life-saving medicine.
×
